

# In-Center Nocturnal Hemodialysis Leads to Improved Serum Phosphorus Levels

Clinical Research Robert I. Lynn, MD<sup>1</sup>; Linda Francisco, MD<sup>2</sup>; Shane Simon<sup>2</sup>; Abbe Volz<sup>2</sup>; Karen Spach, PhD<sup>2</sup>; Ronald Levine, MBA<sup>2</sup>; Robert Provenzano, MD, FACP, FASN<sup>2</sup>

Advancing Kidney Care (1) Nephrology & Hypertension Associates, Bronx, NY, (2) DaVita, Inc., Denver, CO

### INTRODUCTION

Control of serum phosphorous ( $PO_4$ ) remains a challenge in the hemodialysis patient despite increased choices in oral phosphate binders, as well as intensive dietary counseling. Elevated serum  $PO_4$  levels contribute to secondary hyperparathyroidism, both directly, and by limiting the use of vitamin D analogs, and are associated with an increased mortality from cardiovascular disease. Delayed transfer from intracellular fluid stores to the extracellular fluid compartment limits the contribution of conventional, in-center hemodialysis (ICHD) to phosphate balance.

We postulated that in-center nocturnal hemodialysis (NHD), with its longer treatment times, would result in substantially greater  $PO_4$  removal, resulting in a lower serum  $PO_4$ .

#### METHODOLOGY

- Retrospective, longitudinal cohort (n=418)
- Prevalent ICHD converted to NHD
- 6 months pre- and 9 months post-conversion to NHD
- o compared parameters of bone and mineral metabolism prior to their conversion to NHD (baseline, mean 4, 5 and 6 months before NHD) to these same parameters following the start of NHD (final, mean 7, 8 and 9 months post modality change) as shown in Figure 1.

### RESULTS




Figure 1. Methodology: Conversion from ICHD to NHD

Table 1. Median treatment times

	Median hrs/session	Sessions/ wk	Median total time (hrs/wk)
ICHD	4.0 ± 0.04	3	12.0
NHD	7.6 ± 0.04*	3	22.7*

<sup>\*</sup> p<0.001



**Serum Phosphorus** 

Figure 2. Serum Phosphorus Levels Before and After Conversion to NHD




Figure 3. Bone and Mineral Metabolism Markers Before and After Conversion to NHD

## CONCLUSIONS

- Median treatment time is significantly higher on NHD compared to ICHD (Table 1).
- Mean serum PO<sub>4</sub> levels decreased 0.67mg/dl during the first month of NHD and, by 9 months, had fallen significantly from ICHD (baseline) to NHD (Figure 2).
- Ca × Phos product decreased and paracalcitol administration increased significantly from ICHD (baseline) to NHD (p<0.001) (Figure 3).</li>
- PTH fell from ICHD (baseline) to NHD (p=0.10), while calcium levels were unchanged.

#### KEY LEARNINGS

- ✓ When compared to ICHD, NHD resulted in a lower serum PO<sub>4</sub> consistent with enhanced PO<sub>4</sub> removal as a result of the longer dialysis sessions with NHD.
- ✓ The decrease in serum PO₄, Ca × Phos product, and PTH may result in long-term cardiovascular benefits for the NHD patient.
- ✓ In this study we did not control for binder usage. Analysis of binder types and amounts, prior to and after the initiation of NHD, is planned in order to confirm that the nocturnal dialysis treatments were responsible for the observed results.

Our sincere appreciation to the teammates in our nearly 1600 clinics who work every day not only to take care of patients but also to ensure the extensive data collection on which our work is based. We thank DaVita Clinical Research® (DCR), and specifically acknowledge Karen Spach, PhD of DCR for her editorial contribution, in preparing this poster. DCR is committed to advancing the knowledge and practice of kidney care

Correspondence: rlynn@renal-md.com American Nephrology Nurses Association, March 27-30, 2011, Boston, MA